Next Article in Journal
Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy
Next Article in Special Issue
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
Previous Article in Journal
Potentiality, Limitations, and Consequences of Different Experimental Models to Improve Photodynamic Therapy for Cancer Treatment in Relation to Antiangiogenic Mechanism
Previous Article in Special Issue
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
Article

Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment

1
IMFUFA, Department of Science and Environment, Roskilde University, 4000 Roskilde, Denmark
2
Department of Haematology, Zealand University Hospital, Roskilde, 2022 Roskilde, Denmark
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(8), 2119; https://doi.org/10.3390/cancers12082119
Received: 27 June 2020 / Revised: 28 July 2020 / Accepted: 28 July 2020 / Published: 30 July 2020
(This article belongs to the Special Issue New Insights into Myeloproliferative Neoplasms)
(1) Background: myeloproliferative neoplasms (MPNs) are slowly developing hematological cancers characterized by few driver mutations, with JAK2V617F being the most prevalent. (2) Methods: using mechanism-based mathematical modeling (MM) of hematopoietic stem cells, mutated hematopoietic stem cells, differentiated blood cells, and immune response along with longitudinal data from the randomized Danish DALIAH trial, we investigate the effect of the treatment of MPNs with interferon-α2 on disease progression. (3) Results: At the population level, the JAK2V617F allele burden is halved every 25 months. At the individual level, MM describes and predicts the JAK2V617F kinetics and leukocyte- and thrombocyte counts over time. The model estimates the patient-specific treatment duration, relapse time, and threshold dose for achieving a good response to treatment. (4) Conclusions: MM in concert with clinical data is an important supplement to understand and predict the disease progression and impact of interventions at the individual level. View Full-Text
Keywords: blood cancer; myeloproliferative neoplasms; JAK2V617F dynamics; mathematical modeling; personalized treatment blood cancer; myeloproliferative neoplasms; JAK2V617F dynamics; mathematical modeling; personalized treatment
Show Figures

Figure 1

MDPI and ACS Style

Ottesen, J.T.; Pedersen, R.K.; Dam, M.J.B.; Knudsen, T.A.; Skov, V.; Kjær, L.; Andersen, M. Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment. Cancers 2020, 12, 2119. https://doi.org/10.3390/cancers12082119

AMA Style

Ottesen JT, Pedersen RK, Dam MJB, Knudsen TA, Skov V, Kjær L, Andersen M. Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment. Cancers. 2020; 12(8):2119. https://doi.org/10.3390/cancers12082119

Chicago/Turabian Style

Ottesen, Johnny T.; Pedersen, Rasmus K.; Dam, Marc J.B.; Knudsen, Trine A.; Skov, Vibe; Kjær, Lasse; Andersen, Morten. 2020. "Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment" Cancers 12, no. 8: 2119. https://doi.org/10.3390/cancers12082119

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop